The R47H variant in the triggering receptor expressed on myeloid cells 2 gene (TREM2), a modulator of the immune response of microglia, is a strong genetic risk factor for Alzheimer disease (AD) and possibly other neurodegenerative disorders.
A lzheimer disease (AD) is the most common form of agerelated dementia. Typically, AD manifests after 65 years of age (late-onset AD [LOAD] ), although 5% to 10% of patients have early-onset AD. Approximately 13% of earlyonset AD cases are mendelian dominant forms of the disease caused by high-penetrance variants in amyloid precursor protein and presenilins. 1 Although LOAD is traditionally referred to as sporadic, familial clustering has frequently been observed 2 and biological relatives of patients with LOAD are at an increased risk for developing dementia. 3, 4 A twin study 5 estimated the heritability of AD to be as high as 79%. Whole-genome association studies have identified multiple genomic loci/genes that appear to influence disease onset/ progression; however, only 2 of these genetic factors are associated with a significant disease risk: the ε4 allele of apolipoprotein E (ApoE4) (odds ratio, 3.2) and the R47H variant in the triggering receptor expressed on myeloid cells 2 gene (TREM2) (odds ratios, 1.7-4.5). [6] [7] [8] Whereas ApoE4 is common in the white population (minor allele frequency, 12.6% 9 ), TREM2 R47H is rare (minor allele frequency, 0.26%; http://evs .gs.washington.edu/EVS/). In the brain, TREM2 is expressed by microglia. To our knowledge, segregation of R47H with AD in families with LOAD has not been reported. Here we describe a large family with LOAD with multiple affected TREM2 R47H carriers and demonstrate mutation-specific changes in neuropathology and expression of microglial markers in brains.
Methods

Participants
Families with LOAD and control individuals were ascertained and evaluated through the University of Washington Alzheimer Disease Research Center. Examinations, blood sampling, medical record reviews, brain autopsies, and genetic analyses were performed under protocols approved by the institutional review boards of the University of Washington and the Seattle Veterans Affairs Puget Sound Health Care System. Written informed consent was obtained from participants.
Exome Sequencing, Copy-Number Variation Analysis, and Genotyping
Target enrichment was performed by hybridization of shotgun fragment libraries to custom microarrays or to NimbleGen_solution_V2refseq2010.HG19 probe library. Exome sequencing was performed as described previously. 10 Sanger sequencing was used to confirm rare exome variants or evaluate them in other family members. For copy-number variant detection, a customized microarray (Agilent 2 × 400K probes) was designed to detect copy-number variants greater than 10 kbp within 1367 sites predisposed for genomic rearrangements and greater than 50 kbp over the rest of the genome. Array comparative genomic hybridization and analysis were performed as described previously 11 and compared with data from 8900 control individuals. 12 R47H was genotyped using a TaqMan single-nucleotide polymorphism assay (rs75932628 Assayby-Design; Applied Biosystems/Life Technologies).
Postmortem Brain Tissues
Autopsy tissues from members of the LOAD123 family, sporadic LOAD cases, and age-matched nondemented (ND) control individuals were obtained from the University of Washington Neuropathology Core Brain Bank. The average age of the individuals was 84.9 years and the average postmortem interval was 4.5 hours.
Immunohistochemistry
Formaldehyde-fixed paraffin-embedded sections were deparaffinized and autoclaved at 15 psi and 121°C for 20 minutes in citrate buffer pH of 6.0 for antigen retrieval. 
Results
TREM2 R47H in Familial LOAD
The LOAD123 family contains 21 individuals with an AD diagnosis ( Figure 1 ; eTables 1 and 2 in the Supplement). The mean (SD) age at onset was 72.5 (8.2) years, the mean (SD) age at death was 81 (8.4) years, and the mean (SD) disease duration was 7.7 (4.4) years. The pedigree in Figure 1 shows vertical disease transmission to the 3 branches. There is age-at-onset heterogeneity, clustered at early age (60-70 years) but extending to 88 years. We selected 4 affected individuals for exome sequencing ( Figure 1) . Two of them, III-5 and III-12, were additionally screened for structural genome variation, but no shared pathogenic uncommon structural variants were identified (eTable 3 in the Supplement). Shared exome variants were sorted by frequency in the population assuming that LOAD risk variants of strong effect would be uncommon (<5%) or rare (<1%). Five shared identity-by-descent regions contained 9 missense variants with frequency less than 5% (eTable 4 in the Supplement). None of the exomes had rare missense variants in the genes known to cause early-onset AD or frontotemporal dementia. 13 One exome contained a rare missense variant, D353N, in the unc-5 homolog C gene (UNC5C) (rs145155041; minor allele frequency, 0.2% in white individuals; http://evs.gs .washington.edu/EVS/), in which another rare variant (rs137875858) was reported in association with AD. 14 D353N is predicted to be damaging to the protein (PolyPhen2 score, 0.85). The R47H variant in TREM2 was prioritized based on association studies. 6, 7 Sanger sequencing confirmed R47H presence in 11 of 15 affected individuals with available DNA and case II-3 could be inferred as a carrier based on the pedigree structure, for a total of 12 R47H carriers of 16 patients with AD (75%).
In the central branch of the family, of 9 siblings with AD, 5 inherited this variant, and 3 of these transmitted it to their affected offspring. Three unaffected individuals were also deduced or shown to carry the variant: II-4 and III-14, who died before the typical age of LOAD onset (57 and 62 years), and III-20, who died at age 87 ( Figure 1 ). Four other siblings with AD were negative for R47H and did not transmit the disease to their 12 offspring (age range, 64-86 years). We studied the distribution of ApoE and UNC5C alleles in the LOAD123 family. Fourteen of 15 affected individuals and 4 of 10 unaffected individuals had at least 1 ApoE4 allele. Of the 3 individuals who were APOE 4/4 homozygotes, 2 with AD had quite disparate ages at onset-60 and 82 years (IV-55 and III-17)-and the third was unaffected at 74 years (IV-57). UNC5C D353N was transmitted within the central branch of the family; of 8 siblings with AD with available DNA, 3 inherited this variant (III-11, III-13, and III-18) and 1 (III-11) transmitted it to her affected offspring (IV-26 and IV-29).
We genotyped R47H in an additional 130 families with LOAD (713 individuals). Eight R47H carriers were found in 3 white European families (KS, MGK, and #62468) and 1 Japanese family (NOA). Seven of 8 R47H carriers had an AD diagnosis. Of the individuals with AD, 1 of 11 in KS, 2 of 4 in NOA, 2 of 3 in MGK, and 2 of 5 in #62486 had R47H. Assuming 1 founder per family, R47H was present in 3% of familial LOAD cases, 10 times higher than in the general population (http://evs.gs .washington.edu/EVS/). In the 5 relevant families, we assessed the effect of TREM2 genotype on age at onset and duration of disease. The disease onset did not differ between R47H carriers and noncarriers (mean [SD], 73.3 [7.6] years; range, 60-85 years; n = 16 and 73.8 [9.7] years; range, 58-90 years; n = 18, respectively). As expected, disease onset was significantly earlier in the patients with at least 1 ApoE4 allele (mean [SD], 70.74 [7.9] years; range, 56-85 years; n = 23 vs 80.9 [5.8] years; range, 71-90 years; n = 10 for noncarriers of the ApoE4 allele; 2-tailed t test P = .0004). The ApoE genotype of 1 affected patient was not tested and could not be deduced. In the subset of patients with AD with at least 1 ApoE4 allele, the TREM2 genotype did not further reduce the age at onset (mean [SD], 72.9 [6.2] years; range, 60-85 years; n = 13 vs 67.9 [5.3] years; range, 58-82 years; n = 10 for R47H carriers and noncarriers, respectively).
Disease duration did not differ between ApoE4 carriers and noncarriers (mean [SD], 9.4 [6.2] years; range, 3-23 years; n = 20 and 7.5 [3.1] years; range, 3-10 years; n = 4, respectively). However, disease duration was significantly shorter in the TREM2 R47H AD group as a whole (mean [SD], 6.7 [2.8] years; range, 3-11 years; n = 11 vs 11.1 [6.6] years; range, 3-23 years; n = 14 for noncarriers; 2-tailed t test P = .04). This disease duration effect was also seen in the subgroup of ApoE4 carriers with the The small number of patients with AD with ApoE 3/3 genotype and TREM2 R47H (n = 2) precluded a statistical test of ageat-onset effects of R47H, but there was no apparent change. These 2 patients had onset at 78 and 81 years (mean, 79.5 years) compared with a range of 71 to 90 years (n = 8; mean [SD], 81.3 [6.5] years) for patients with ApoE 3/3 and without TREM2 R47H. It was not possible to assess the effect of R47H on disease duration in the absence of an ApoE4 allele as both patients are still living.
Clinical and Neuropathological Findings in the LOAD123 Family
Clinical presentations of the patients with AD positive and negative for R47H were similar; most patients showed slowly progressive dementia with memory problems as the initial symptom. Initial psychobehavioral signs were present in 2 patients: a TREM2 R47H carrier (III-15) had hallucinations and aggression early in the disease and a noncarrier (III-9) developed severe paranoia. Another R47H carrier (III-11) was diagnosed as having Parkinson disease (PD) 3 years after the onset of the memory deficit.
Autopsies were performed on 12 patients, 10 with clinically diagnosed dementia and 2 unaffected relatives (Table) . Neuropathologic examination confirmed the diagnosis of AD in 9 patients with dementia with Braak stages of 5 or 6 (9 of 10) and Consortium to Establish a Registry for Alzheimer's Dis- III-13 had very late-onset dementia (88 years), died at age 96, and had Braak stage 3 and CERAD score of A. She was ApoE 3/3 and R47H negative. It is of interest that she carried the UNC5C D353N variant that is predicted to be pathogenic.
Their ND relatives (III-20 and IV-27) both had a Braak stage of 3 and a CERAD score of A. Four patients with AD (3 R47H carriers [III-11, III-12, and III-15] and 1 noncarrier [III-9]) had notable vascular pathology, presumably at least partly related to their advanced ages of 82 to 93 years (Table) .
In addition to LOAD, the R47H variant has been reported to be associated with a spectrum of neurodegenerative disorders including frontotemporal dementia, 18, 19 PD, 20 and amyotrophic lateral sclerosis. 21 We evaluated markers characteristic of these pathologies (α-synuclein and TDP-43 deposits) in 10 individuals from the LOAD123 family, 8 of whom had AD and 2 were ND (Table) . α-Synuclein immunopositive inclusions and neurites were most common in the amygdala (6 of 8 with AD; 1 of 2 ND) and less common in the substantia nigra (4 of 8 with AD; 1 of 2 ND), cingulate gyrus (4 of 8 with AD; 0 of 2 ND), medulla (3 of 8 with AD; 1 of 2 ND), and frontal cortex (3 of 8 with AD; 0 of 2 ND). Both III-11 and III-15 had Lewy bodies in the substantia nigra, mild neuronal loss, and gliosis suggestive of PD-like pathology. Scoring of α -synuclein deposition in the 5 brain regions indicated that α-synuclein inclusions were more frequent (P= .06) and more severe (P = .02) in R47H carriers compared with their noncarrier relatives. Inclusions of TDP-43 were observed in 5 of the LOAD123 AD cases, 4 of these with neocortical pathologic changes. Both ND relatives also had TDP-43 deposits in the amygdala, and the one without the R47H variant had additional pathology in the parahippocampal gyrus and the frontal cortex. Scoring of TDP-43 deposits in 4 regions did not reveal differences between R47H carriers and noncarriers. Two women were of particular interest. The person with earliest age at onset (IV-55, 60 years) carried both APOE 4/4 and TREM2 R47H. A female relative (III-17) with the same genotype had much later onset at 82 years. Both patients had a Braak stage of 5 and a CERAD score of C and neither had vascular pathology.
Decreased Iba1 Level Is a Characteristic Feature of TREM2 R47H Microglia
To analyze the cellularity and activation state of microglia, we performed immunohistochemistry of postmortem brains with panmicroglial marker Iba1 and activation-specific marker MHCII. We chose the hippocampus as a representative area affected in AD and as a region with the highest number of microglia cells. Three groups were compared: (1) patients with AD heterozygous for R47H (R47H_AD group); (2) patients with AD with normal TREM2 genotype (AD group); and (3) age-matched ND control individuals (ND group) (eTable 5 in the Supplement). The Iba1 signal was reduced in all AD cases (Figure 2A (Figure 3) . In addition to per-area analysis, we performed per-large-object quantification (where large objects corresponded to cell bodies; see the eAppendix in the Supplement). There was a strong correlation between the total positive area and the total positive area of large (cell-body sized) particles. In R47H_AD cases with decreased density of Iba1 signal per Microglia quantification and assessment of activated state are complex and signal intensity alone may not reflect the morphological changes that can be discerned by an observer. Therefore, we analyzed MHCII and Iba1 immunoreactivities in the white matter of the hippocampus using an algorithm to include signal intensity and cellular morphology. We found significantly increased numbers of MHCII-positive, activatedshape microglia in all AD groups compared with control individuals (AD: 2.5, R47H_AD: 2.7, and control: 1.0; P < .01; Figure 4 ), suggesting higher MHCII reactivity in AD microglia. Again, we found significantly decreased Iba1 reactivity in white matter in the R47H_AD group compared with control individuals (1-way analysis of variance; P < .001); furthermore, there was a significant decrease of Iba1 labeling in the R47H_AD group compared with the AD group (1-way analysis of variance; F 2,13 = 25.96; P < .001; Tukey post-test; mean, 1.143 for R47H_AD vs 2.333 for AD; mean difference, 1.19; 95% CI of difference, 0.5875-1.793; P < .001). In aggregate, the area signal quantification and morphometry confirmed that the substantial reduction of Iba1 level is a characteristic feature of TREM2 R47H microglia that distinguishes it from other AD cases.
Discussion
Although it has been established by population-based studies that the R47H variant of TREM2 is a risk factor for AD, to our knowledge, the effect of this variant at the family level has not been described. We have characterized a large multigeneration family with LOAD, in which 75% of patients with AD had the R47H variant of TREM2 and vertical transmission of disease was observed only through R47H carriers. The unusually high incidence of AD in this family is likely an additive effect of ApoE4, TREM2 R47H, and, possibly, additional genes/ risk factors. Clinically, family members with the TREM2 R47H variant had a shorter duration of disease than those without the variant. Our data suggest that in these families, ApoE4 primarily affects age at onset and TREM2 R47H shortens disease duration.
Patients with R47H did not manifest any features distinguishable from classic AD neuropathology. We did find evidence for an increased frequency and severity of α-synucleinopathy in the R47H carriers that needs to be confirmed in a larger-scale study. The link between α-synuclein deposition in TREM2 R47H AD (our study), the association of R47H with PD, 20 and deficient phagocytosis in cells overexpressing this variant 22 are especially intriguing. A previous study offered mechanistic clues about the role the TREM2 receptor may have in microglial sensing of β-amyloid deposits 23 and, possibly, other aggregation-prone proteins, such as α-synuclein. The search for causes and therapies for AD has primarily concentrated on neurons and less on glia and microglia. Although the presence of activated microglia surrounding amyloid deposits and neurofibrillary tangles is well documented in AD and other age-related dementia, these changes have long been considered secondary events. One exception is polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, a rare recessive systemic disorder that manifests with an early-onset dementia and bone cysts. In polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, the primary trigger of neurodegeneration is loss of function of the microglial TREM2-TYROBP receptorsignaling complex. 24 The contribution of microglial immunity to the neurodegenerative process is now evidenced by Gray matter and white matter were assessed. The density of the signal was averaged from 3 areas measured for each individual. Groups are compared using a 2-tailed t test. AD group indicates patients with AD with normal TREM2 (n = 6); control, the nondemented cases (n = 3); and R47H_AD, patients with AD who carry TREM2 R47H (n = 7). All R47H_AD individuals and 3 of 6 AD group individuals are from the LOAD123 family; the others are sporadic cases. The error bars indicate 1 SD. a P < .05. receptor for neuronal health. Our study further supports its role as a risk factor in familial LOAD. Consistent with some, 6 but not all, studies, 6, 19 we did not observe an R47H influence on age at onset. However, we noticed that our patients with AD with R47H had shortened disease duration that presumably reflects an accelerated disease progression. The link between R47H and the ultimate life expectancy of patients with AD awaits confirmation in a larger sample. Ionized calcium-binding adapter molecule 1 has been considered a proinflammatory protein expressed by both resting and activated microglial cells. It is used as a robust marker to characterize microglia. Ionized calcium-binding adapter molecule 1 is highly upregulated in microglia in murine models of acute neuroinflammation 29, 30 and in a mouse microglial cell line on stimulation with β-amyloid 42 peptide. 31 In contrast
to acute neuroinflammation, we demonstrated here that the chronic activated phenotype adopted by AD microglia is characterized by a substantial decrease of Iba1 level, and this lowered expression is exacerbated in R47H carriers. Our observation of a decreased tissue level of Iba1 across all examined regions of AD brain could be explained by reduced microglial cellularity or by loss of the Iba1 by a substantial fraction of microglia. A study of a large sporadic AD cohort found that a substantial fraction of AD microglia was negative for Iba1 and positive for MHCII, while the total number of microglial cells in fact did not differ between those with AD and control individuals. 
Conclusions
The LOAD123 family reported herein exemplifies the complexity of the genetic landscape of LOAD, even in single pedigrees with an apparent autosomal dominant pattern of inheritance. In this pedigree, it is likely that ApoE4, TREM2 R47H, and rare variants in other genes, such as UNC5C D353N, are responsible for the marked occurrence of AD in the family. Our results also support the role of the TREM2 receptor in microglial clearance of aggregated proteins that is compromised in R47H carriers who may have shortened duration of disease.
